AWM
ABUS icon

Avior Wealth Management’s Arbutus Biopharma ABUS Stock Holding History

Avior Wealth Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-24
Closed -$61 – 2258
2024
Q1 		$61 Buy
+24
New +$62 ﹤0.01% 3399

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Avior Wealth Management's ABUS Position: Q2 2024 in Review

Avior Wealth Management sold out of Arbutus Biopharma (ABUS) in Q2 2024, closing a stake of 24 shares — an estimated $61 sold.

Avior Wealth Management first reported a position in ABUS in Q1 2024 and held it in 1 quarter. The position peaked at $61 in Q1 2024. 131 funds tracked by Wall St. Rank hold ABUS as of Q2 2024.

  • Avior Wealth Management reported no remaining Arbutus Biopharma position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 24 Arbutus Biopharma shares in Q2 2024, an estimated $61.
  • Avior Wealth Management first reported a position in Arbutus Biopharma in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Arbutus Biopharma position peaked at $61 in Q1 2024.
  • 131 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.